PSMA (prostate specific membrane antigen) shows promise as a general cancer marker in addition to prostate cancer
This article was originally published in Clinica
Executive Summary
Prostate specific membrane antigen (PSMA) can act as a diagnostic for a wide variety of cancers in addition to prostate cancer, researchers at the Memorial Sloan-Kettering Cancer Center in Princeton, New Jersey have confirmed. However, unlike prostate cancer where it occurs in tumour cells, in these cancers PSMA appears to be associated with the growth of new blood vessels in malignant tissue, lead researcher Dr Sam Chang reports in Cancer Research (July).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.